Aditxt, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Aditxt, Inc. (ADTX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of $42.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-03-31
- Aditxt, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was $42.79M, a 22.18% increase from fiscal 2024.
- Aditxt, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was $35.02M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month |
|---|---|
| 2025-12-31 | $42.79M 10-K · filed 2026-03-31 |
| 2024-12-31 | $35.02M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |